Literature DB >> 29849700

Natural Products as an Emerging Therapeutic Alternative in the Treatment of Neurological Disorders.

Nasiara Karim1, Heba Abdelhalim2, Navnath Gavande3, Imran Khan4, Haroon Khan5.   

Abstract

Entities:  

Year:  2018        PMID: 29849700      PMCID: PMC5903314          DOI: 10.1155/2018/3056847

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


× No keyword cloud information.
Neurological disorders are common and represent a major public health problem. Neurological disorders include dementia, epilepsy, headache disorders, multiple sclerosis, and neuroinfections, neurological disorders associated with malnutrition, pain associated with neurological disorders, Parkinson's disease, stroke, and traumatic brain injuries. There are approximately 450 million of world population suffering from these mental disorders [1]. For example, 50 million people have epilepsy and this number is increasing day by day [2]. The number of people suffering from dementia and memory disorders is projected to be doubled every 20 years. Currently, 322 million people suffer from major depression [3] and this number is on the rise. Neurological disorders constitute over 6% of the global burden of disease [4]. This burden is especially high in many low- and middle-income countries. Considerable efforts have been made in recent decades to discover substances which can help prevent these serious neurological disorders. Natural products are small molecules found in divergent natural sources. They possess a coveted position in the treatment of all human illnesses including neurological disorders. They are believed to be the single most important source of drug leads [5]. The importance of plant derived natural products for the treatment of neurological disorders is evident by the fact that most of the earlier drugs used for the treatment of neurological disorders were derived from plants including opioids alkaloids [6], galantamine [7], and anticholinesterases like physostigmine and neostigmine [8]. During the last decade out of total 26 natural drugs approved, 7 were for the treatment of neurological disorders, out of which 3 were for Parkinson's disease [9]. This special issue focuses on original contributions for natural products being useful in various neurological disorders including anxiety, depression, stroke, epilepsy, and other CNS disorders and their possible mechanisms of action.
  8 in total

1.  Basic opioid pharmacology: an update.

Authors:  Hasan Pathan; John Williams
Journal:  Br J Pain       Date:  2012-02

2.  The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys.

Authors:  Ronald C Kessler; Sergio Aguilar-Gaxiola; Jordi Alonso; Somnath Chatterji; Sing Lee; Johan Ormel; T Bedirhan Ustün; Philip S Wang
Journal:  Epidemiol Psichiatr Soc       Date:  2009 Jan-Mar

Review 3.  The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.

Authors:  Steven S Clevenger; Devvrat Malhotra; Jonathan Dang; Brigitte Vanle; Waguih William IsHak
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-01

4.  Acetylcholinesterase inhibitors: pharmacology and toxicology.

Authors:  Mirjana B Colović; Danijela Z Krstić; Tamara D Lazarević-Pašti; Aleksandra M Bondžić; Vesna M Vasić
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

5.  Medical management of Parkinson's disease: focus on neuroprotection.

Authors:  Marie-Catherine Boll; Mireya Alcaraz-Zubeldia; Camilo Rios
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

Review 6.  New concepts in nutraceuticals as alternative for pharmaceuticals.

Authors:  Hamid Nasri; Azar Baradaran; Hedayatollah Shirzad; Mahmoud Rafieian-Kopaei
Journal:  Int J Prev Med       Date:  2014-12

7.  The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010.

Authors:  Harvey A Whiteford; Alize J Ferrari; Louisa Degenhardt; Valery Feigin; Theo Vos
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

8.  An estimate of the prevalence of epilepsy in Sub-Saharan Africa: A systematic analysis.

Authors:  Abigail Paul; Davies Adeloye; Rhiannon George-Carey; Ivana Kolčić; Liz Grant; Kit Yee Chan
Journal:  J Glob Health       Date:  2012-12       Impact factor: 4.413

  8 in total
  3 in total

Review 1.  Potential therapeutics against neurological disorders: Natural products-based drugs.

Authors:  Abdur Rauf; Md Mominur Rahman
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

2.  Neuropharmacological Assessment of the Hydroethanolic Leaf Extract of Calotropis procera (Ait). R. Br. (Apocynaceae) in Mice.

Authors:  Ernest Obese; Elvis Ofori Ameyaw; Robert Peter Biney; Emmanuel Awintiig Adakudugu; Eric Woode
Journal:  Scientifica (Cairo)       Date:  2021-07-01

Review 3.  A Review on Worldwide Ephedra History and Story: From Fossils to Natural Products Mass Spectroscopy Characterization and Biopharmacotherapy Potential.

Authors:  Khaoula Elhadef; Slim Smaoui; Mariam Fourati; Hajer Ben Hlima; Ahlem Chakchouk Mtibaa; Imen Sellem; Karim Ennouri; Lotfi Mellouli
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-30       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.